196 related articles for article (PubMed ID: 25842259)
1. The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase.
Zhao X; Huang M; Zhu Q; Wang T; Liu Q
Magn Reson Imaging; 2015 Jul; 33(6):768-73. PubMed ID: 25842259
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis.
Li XM; Chen Z; Xiao EH; Shang QL; Ma C
World J Gastroenterol; 2017 May; 23(17):3133-3141. PubMed ID: 28533670
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
4. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
[TBL] [Abstract][Full Text] [Related]
7. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
8. Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.
Peña CS; Saini S; Baron RL; Hamm BA; Morana G; Caudana R; Giovagnoni A; Villa A; Carriero A; Mathieu D; Bourne MW; Kirchin MA; Pirovano G; Spinazzi A
Korean J Radiol; 2001; 2(4):210-5. PubMed ID: 11754328
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
10. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
[TBL] [Abstract][Full Text] [Related]
11. Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.
Kim HY; Choi JY; Park CH; Song MJ; Song DS; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE
J Gastroenterol; 2013 Oct; 48(10):1180-7. PubMed ID: 23354621
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
13. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
15. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
Liu C; Sun Y; Yang Y; Feng Y; Xie X; Qi L; Liu K; Wang X; Zhu Q; Zhao X
Eur Radiol; 2021 Aug; 31(8):5840-5850. PubMed ID: 33533990
[TBL] [Abstract][Full Text] [Related]
16. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
17. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
18. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis.
Akpinar E; Turkbey B; Karcaaltincaba M; Balli O; Akkapulu N; Balas S; Tirnaksiz B; Akata D; Akhan O
J Magn Reson Imaging; 2009 Sep; 30(3):578-85. PubMed ID: 19711404
[TBL] [Abstract][Full Text] [Related]
19. Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers.
Planchamp C; Gex-Fabry M; Becker CD; Pastor CM
Invest Radiol; 2007 Jul; 42(7):513-21. PubMed ID: 17568274
[TBL] [Abstract][Full Text] [Related]
20. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
